Domenica Lorusso

Research interests

Publications

• Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2313811

• ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2023.11.015

• First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.23.00914

• Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.07.011

• ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

  International Journal of Gynecological Cancer · 2023 · https://doi.org/10.1136/ijgc-2023-004429

• European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.11.013

• Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2112435

• Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00056-5

• ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

  International Journal of Gynecological Cancer · 2020 · https://doi.org/10.1136/ijgc-2020-002230

• A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1808424

• Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911361

• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz062

• Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy001

• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32440-6

• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32440-6

• ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv484

Current projects

No projects listed.